Literature DB >> 22320958

Clinical significance of mTOR and p-mTOR protein expression in human colorectal carcinomas.

Di Wang1, Jian Chen, Fengjie Guo, Hui Chen, Zhi Duan, Mei-Yan Wei, Qi-Mei Xu, Liang-Hua Wang, Mei-Zuo Zhong.   

Abstract

AIM: To investigate the significance of mammalian target of rapamycin (mTOR) and its active form, p-mTOR in colorectal carcinomas.
METHODS: Immunohistochemistry was used to detect the expression of mTOR and p-mTOR proteins in 108, 40 and 40 tissue samples from colorectal carcinoma, normal colonic mucosa and adenomatous polyps samples, respectively. The correlation of mTOR and p-mTOR expression with clinicopathological characteristics of colorectal carcinoma was analyzed.
RESULTS: The positive rates of mTOR and p-mTOR were significantly higher in colorectal carcinoma (61.1% and 61.1%, respectively, p<0.05) than in normal colonic mucosa (7.5% and 2.5%) and adenomatous polyps (27.5% and 20%). Overexpression of total mTOR protein was significantly associated with T1/T2 stage tumors, lymph node metastasis, distal metastasis) and degree of differentiation. p-mTOR overexpression was additionaly linked with degree of differentiation and TNM stage.
CONCLUSION: The overexpression of mTOR and p-mTOR may play important roles in colorectal carcinogenesis with relations to the degree of differentiation, invasiveness and metastasis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22320958

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  6 in total

1.  Expression and clinical significance of mammalian target of rapamycin/P70 ribosomal protein S6 kinase signaling pathway in human colorectal carcinoma tissue.

Authors:  Qingjun Lu; Jieshu Wang; Gang Yu; Tianhua Guo; Chun Hu; Peng Ren
Journal:  Oncol Lett       Date:  2015-05-19       Impact factor: 2.967

2.  Increased serum leptin level in overweight patients with colon carcinoma: A cross-sectional and prospective study.

Authors:  Di Wang; Lichen Gao; Kuiyu Gong; Qin Chai; Guihua Wang
Journal:  Mol Clin Oncol       Date:  2016-11-21

3.  Expression of phospho-mTOR kinase is abundant in colorectal cancer and associated with left-sided tumor localization.

Authors:  Nathaniel Melling; Ronald Simon; Jakob R Izbicki; Luigi M Terracciano; Carsten Bokemeyer; Guido Sauter; Andreas H Marx
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

4.  Phosphorylated Mammalian Target of Rapamycin p-mTOR Is a Favorable Prognostic Factor than mTOR in Gastric Cancer.

Authors:  Guo-Dong Cao; Xing-Yu Xu; Jia-Wei Zhang; Bo Chen; Mao-Ming Xiong
Journal:  PLoS One       Date:  2016-12-22       Impact factor: 3.240

5.  Novel cancer chemotherapy hits by molecular topology: dual Akt and Beta-catenin inhibitors.

Authors:  Riccardo Zanni; Maria Galvez-Llompart; Cecilia Morell; Nieves Rodríguez-Henche; Inés Díaz-Laviada; Maria Carmen Recio-Iglesias; Ramon Garcia-Domenech; Jorge Galvez
Journal:  PLoS One       Date:  2015-04-24       Impact factor: 3.240

6.  Activation of the PI3K/Akt/mTOR/p70S6K pathway is involved in S100A4-induced viability and migration in colorectal cancer cells.

Authors:  Haiyan Wang; Liang Duan; Zhengyu Zou; Huan Li; Shimei Yuan; Xian Chen; Yunyuan Zhang; Xueru Li; Hui Sun; He Zha; Yan Zhang; Lan Zhou
Journal:  Int J Med Sci       Date:  2014-06-08       Impact factor: 3.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.